Efficacy and Safety of Eplerenone for Treating Chronic Kidney Disease: A Meta-Analysis
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and Safety of Eplerenone for Treating Chronic Kidney Disease: A Meta-Analysis
Authors
Keywords
-
Journal
International Journal of Hypertension
Volume 2023, Issue -, Pages 1-18
Publisher
Hindawi Limited
Online
2023-03-16
DOI
10.1155/2023/6683987
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of eplerenone treatment for patients with diabetic nephropathy: A meta-analysis
- (2022) Honglei Hu et al. PLoS One
- Lowest nocturnal systolic blood pressure is related to heavy proteinuria and outcomes in elderly patients with chronic kidney disease
- (2021) Xinru Guo et al. Scientific Reports
- Effect of Mineralocorticoid Receptor Antagonism and ACE Inhibition on Angiotensin Profiles in Diabetic Kidney Disease: An Exploratory Study
- (2021) Johannes J. Kovarik et al. Diabetes Therapy
- Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
- (2021) Nina Vodošek Hojs et al. Pharmaceuticals
- An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines
- (2020) Nicholas M. Selby et al. DIABETES OBESITY & METABOLISM
- Effect of high-dose mineralocorticoid receptor antagonist eplerenone on urinary albumin excretion in patients with type 2 diabetes and high cardiovascular risk: Data from the MIRAD trial
- (2020) Niels H. Brandt-Jacobsen et al. DIABETES & METABOLISM
- The effect of aldosterone and aldosterone blockade on the progression of chronic kidney disease: a randomized placebo-controlled clinical trial
- (2020) Hitoshi Minakuchi et al. Scientific Reports
- A Prospective Single-Blind Randomized Trial of Ramipril, Eplerenone and Their Combination in Type 2 Diabetic Nephropathy
- (2020) Mostafa El Mokadem et al. CardioRenal Medicine
- Effects of telmisartan on proteinuria and systolic blood pressure in dogs with chronic kidney disease
- (2020) Yuichi Miyagawa et al. RESEARCH IN VETERINARY SCIENCE
- Hospitalizations among adults with chronic kidney disease in the United States: A cohort study
- (2020) Sarah J. Schrauben et al. PLOS MEDICINE
- Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS‐HF trial
- (2019) João Pedro Ferreira et al. EUROPEAN JOURNAL OF HEART FAILURE
- Efficacy and safety of mineralocorticoid receptor antagonists with ACEI/ARB treatment for diabetic nephropathy: A meta‐analysis
- (2019) Chao Zuo et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- A randomized, double-blind clinical trial of canrenone vs hydrochlorothiazide in addition to angiotensin II receptor blockers in hypertensive type 2 diabetic patients
- (2018) Giuseppe Derosa et al. Drug Design Development and Therapy
- Antialbuminuric effect of eplerenone in comparison to thiazide diuretics in patients with hypertension
- (2017) Toshiki Sawai et al. Journal of Clinical Hypertension
- Low dose-eplerenone treatment decreases aortic stiffness in patients with resistant hypertension
- (2017) Tatjana Kalizki et al. Journal of Clinical Hypertension
- A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and/or Chronic Kidney Disease
- (2016) Naoki Sato et al. CIRCULATION JOURNAL
- Angiotensin II receptor blocker combined with eplerenone or hydrochlorothiazide for hypertensive patients with diabetes mellitus
- (2016) Shigehiro Karashima et al. CLINICAL AND EXPERIMENTAL HYPERTENSION
- Add-On Use of Eplerenone Is Effective for Lowering Home and Ambulatory Blood Pressure in Drug-Resistant Hypertension
- (2016) Kazuo Eguchi et al. Journal of Clinical Hypertension
- Safety and Antihypertensive Effect of Selara® (Eplerenone): Results from a Postmarketing Surveillance in Japan
- (2016) Shoko Takahashi et al. International Journal of Hypertension
- Renoprotective effects of thiazides combined with loop diuretics in patients with type 2 diabetic kidney disease
- (2014) Taro Hoshino et al. Clinical and Experimental Nephrology
- Comparison of the Antialbuminuric Effects of Benidipine and Hydrochlorothiazide in Renin-Angiotensin System (RAS) Inhibitor-Treated Hypertensive Patients with Albuminuria: the COSMO-CKD (COmbination Strategy on Renal Function of Benidipine or Diuretics TreatMent with RAS inhibitOrs in a Chronic Kidney Disease Hypertensive Population) Study
- (2014) Katsuyuki Ando et al. International Journal of Medical Sciences
- Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial
- (2014) Katsuyuki Ando et al. Lancet Diabetes & Endocrinology
- Safety and Efficacy of Eplerenone in Patients at High Risk for Hyperkalemia and/or Worsening Renal Function
- (2013) Romain Eschalier et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Eplerenone Attenuates Pulse Wave Reflection in Chronic Kidney Disease Stage 3–4 - A Randomized Controlled Study
- (2013) Lene Boesby et al. PLoS One
- The Enhanced Renin-Angiotensin-Aldosteron System Pharmacological Blockade - Which is the Best?
- (2012) Leszek Tylicki et al. KIDNEY & BLOOD PRESSURE RESEARCH
- Changes in Albuminuria Predict Mortality and Morbidity in Patients with Vascular Disease
- (2011) R. E. Schmieder et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Moderate Antiproteinuric Effect of Add-On Aldosterone Blockade with Eplerenone in Non-Diabetic Chronic Kidney Disease. A Randomized Cross-Over Study
- (2011) Lene Boesby et al. PLoS One
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now